Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02 2024 - 3:05PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultrarare genetic diseases, today
announced that Emil D. Kakkis, M.D., Ph.D., the company's chief
executive officer and president, will present at the 42nd Annual
J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at
3:00 PM PT.
The live and archived webcast of the presentation
will be accessible from the company’s website
at https://ir.ultragenyx.com/events-presentations. The replay
of the webcast will be available for 30 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact – Ultragenyx Pharmaceutical, Inc.InvestorsJoshua Higa
ir@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024